

Laura Biganzoli

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1432193/publications.pdf>

Version: 2024-02-01

112
papers

5,080
citations

109137

35
h-index

91712

69
g-index

115
all docs

115
docs citations

115
times ranked

6760
citing authors

#	ARTICLE	IF	CITATIONS
1	Abstract P5-13-13: <i>PIK3CA</i> mutations co-occurring with copy number gain identify patients with adverse outcome and potentially different treatment sensitivity among hormone receptor positive and HER2 negative metastatic breast cancer. <i>Cancer Research</i> , 2022, 82, P5-13-13-P5-13-13.	0.4	0
2	Emetogenicity of Antibody-Drug Conjugates (ADCs) in Solid Tumors with a Focus on Trastuzumab Deruxtecan: Insights from an Italian Expert Panel. <i>Cancers</i> , 2022, 14, 1022.	1.7	10
3	PIK3CA co-occurring mutations and copy-number gain in hormone receptor positive and HER2 negative breast cancer. <i>Npj Breast Cancer</i> , 2022, 8, 24.	2.3	9
4	Definition of High-Risk Early Hormone-Positive HER2 ⁺ Negative Breast Cancer: A Consensus Review. <i>Cancers</i> , 2022, 14, 1898.	1.7	20
5	Chemotherapy and gene expression profiling in older early luminal breast cancer patients: An International Society of Geriatric Oncology systematic review. <i>European Journal of Cancer</i> , 2022, 172, 158-170.	1.3	4
6	CDK4/6 inhibitors: A focus on biomarkers of response and post-treatment therapeutic strategies in hormone receptor-positive HER2-negative breast cancer. <i>Cancer Treatment Reviews</i> , 2021, 93, 102136.	3.4	25
7	Circulating tumor cells and palbociclib treatment in patients with ER-positive, HER2-negative advanced breast cancer: results from a translational sub-study of the TReND trial. <i>Breast Cancer Research</i> , 2021, 23, 38.	2.2	14
8	Precision Oncology via NMR-Based Metabolomics: A Review on Breast Cancer. <i>International Journal of Molecular Sciences</i> , 2021, 22, 4687.	1.8	23
9	Multigene tests for breast cancer: the physician's perspective. <i>Oncotarget</i> , 2021, 12, 936-947.	0.8	9
10	Circulating Biomarkers of CDK4/6 Inhibitors Response in Hormone Receptor Positive and HER2 Negative Breast Cancer. <i>Cancers</i> , 2021, 13, 2640.	1.7	8
11	A Serum Metabolomics Classifier Derived from Elderly Patients with Metastatic Colorectal Cancer Predicts Relapse in the Adjuvant Setting. <i>Cancers</i> , 2021, 13, 2762.	1.7	14
12	Systemic therapy for early breast cancer in older adults. <i>Current Opinion in Oncology</i> , 2021, Publish Ahead of Print, 574-583.	1.1	1
13	Updated recommendations regarding the management of older patients with breast cancer: a joint paper from the European Society of Breast Cancer Specialists (EUSOMA) and the International Society of Geriatric Oncology (SIOG). <i>Lancet Oncology</i> , The, 2021, 22, e327-e340.	5.1	121
14	A Dose-finding Study of Metronomic Oral Vinorelbine in Combination With Oral Cyclophosphamide and Bevacizumab in Patients With Advanced Breast Cancer. <i>Clinical Breast Cancer</i> , 2021, 21, e332-e339.	1.1	3
15	Exploring Serum NMR-Based Metabolomic Fingerprint of Colorectal Cancer Patients: Effects of Surgery and Possible Associations with Cancer Relapse. <i>Applied Sciences (Switzerland)</i> , 2021, 11, 11120.	1.3	3
16	Is There Still a Role for Endocrine Therapy Alone in HR+/HER2 ⁻ Advanced Breast Cancer Patients? Results from the Analysis of Two Data Sets of Patients Treated with High-Dose Fulvestrant as First-Line Therapy in the Real-World Setting: The EVA and GIM-13 AMBRA Studies. <i>Breast Care</i> , 2020, 15, 30-37.	0.8	0
17	Expanding the Scope of Geriatric Assessment for the Management of Cancer in Older Adults. <i>JAMA Oncology</i> , 2020, 6, 204.	3.4	2
18	Practice patterns regarding drains management in breast surgery: Results of a survey of Senonetwork Italia breast centers. <i>Breast Journal</i> , 2020, 26, 560-562.	0.4	0

#	ARTICLE	IF	CITATIONS
19	Endocrine therapy for hormone receptor-positive, HER2-negative metastatic breast cancer: extending endocrine sensitivity. <i>Future Oncology</i> , 2020, 16, 129-145.	1.1	5
20	A Randomized Placebo Controlled Phase II Trial Evaluating Exemestane with or without Enzalutamide in Patients with Hormone Receptor-Positive Breast Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 6149-6157.	3.2	29
21	EFFECT: a randomized phase II study of efficacy and impact on function of two doses of nab-paclitaxel as first-line treatment in older women with advanced breast cancer. <i>Breast Cancer Research</i> , 2020, 22, 83.	2.2	6
22	The Conundrum of the Association of Chemotherapy With Survival Outcomes Among Elderly Patients With Curable Luminal Breast Cancer. <i>JAMA Oncology</i> , 2020, 6, 1535.	3.4	10
23	Cell-Free DNA-Methylation-Based Methods and Applications in Oncology. <i>Biomolecules</i> , 2020, 10, 1677.	1.8	31
24	The requirements of a specialist breast centre. <i>Breast</i> , 2020, 51, 65-84.	0.9	111
25	Plasma Thymidine Kinase Activity as a Biomarker in Patients with Luminal Metastatic Breast Cancer Treated with Palbociclib within the TReND Trial. <i>Clinical Cancer Research</i> , 2020, 26, 2131-2139.	3.2	40
26	Neoadjuvant nab-paclitaxel in breast cancer: who stands to benefit?. <i>Chinese Clinical Oncology</i> , 2020, 9, 42-42.	0.4	0
27	Capivasertib, an AKT Kinase Inhibitor, as Monotherapy or in Combination with Fulvestrant in Patients with AKT1 E17K-Mutant, ER-Positive Metastatic Breast Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 3947-3957.	3.2	54
28	A multi-stakeholder approach in optimising patients' needs in the benefit assessment process of new metastatic breast cancer treatments. <i>Breast</i> , 2020, 52, 78-87.	0.9	7
29	Inclusion of Platinum Agents in Neoadjuvant Chemotherapy Regimens for Triple-Negative Breast Cancer Patients: Development of GRADE (Grades of Recommendation, Assessment, Development and) Tj ETQq1 1 0,784314,rgBT /Over 1137.	1.7	22
30	Early triple negative breast cancer: Are we getting better outcomes? A retrospective analysis from a single institution. <i>Breast Journal</i> , 2019, 25, 1225-1229.	0.4	0
31	European Guidelines on the Organisation of Breast Centres and Voluntary Certification Processes. <i>Breast Care</i> , 2019, 14, 359-365.	0.8	4
32	Metabolomic analysis of serum may refine 21-gene expression assay risk recurrence stratification. <i>Npj Breast Cancer</i> , 2019, 5, 26.	2.3	12
33	The optimal duration of adjuvant endocrine therapy in early luminal breast cancer: A concise review. <i>Cancer Treatment Reviews</i> , 2019, 74, 29-34.	3.4	23
34	<p>Treating advanced breast cancer with metronomic chemotherapy: what is known, what is new and what is the future?</p>. <i>OncoTargets and Therapy</i> , 2019, Volume 12, 2989-2997.	1.0	23
35	HER2-targeted treatment for older patients with breast cancer: An expert position paper from the International Society of Geriatric Oncology. <i>Journal of Geriatric Oncology</i> , 2019, 10, 1003-1013.	0.5	40
36	Cyclin-Dependent Kinase 4/6 Inhibitors in Neoadjuvant Endocrine Therapy of Hormone Receptor-Positive Breast Cancer. <i>Clinical Breast Cancer</i> , 2019, 19, 392-398.	1.1	12

#	ARTICLE	IF	CITATIONS
37	Clinical outcomes after palbociclib with or without endocrine therapy in postmenopausal women with hormone receptor positive and HER2-negative metastatic breast cancer enrolled in the TReND trial. <i>Breast Cancer Research</i> , 2019, 21, 71.	2.2	19
38	Prognostic role of serum thymidine kinase 1 activity in patients with hormone receptor-positive metastatic breast cancer: Analysis of the randomised phase III Evaluation of Faslodex versus Exemestane Clinical Trial (EFFECT). <i>European Journal of Cancer</i> , 2019, 114, 55-66.	1.3	30
39	Trends in axillary lymph node dissection for early-stage breast cancer in Europe: Impact of evidence on practice. <i>Breast</i> , 2019, 45, 89-96.	0.9	25
40	Quality of life under extended continuous versus intermittent adjuvant letrozole in lymph node-positive, early breast cancer patients: the SOLE randomised phase 3 trial. <i>British Journal of Cancer</i> , 2019, 120, 959-967.	2.9	5
41	Pembrolizumab plus trastuzumab in trastuzumab-resistant, advanced, HER2-positive breast cancer (PANACEA): a single-arm, multicentre, phase 1b-2 trial. <i>Lancet Oncology</i> , The, 2019, 20, 371-382.	5.1	327
42	Eribulin Mesylate as Third or Subsequent Line Chemotherapy for Elderly Patients with Locally Recurrent or Metastatic Breast Cancer: A Multicentric Observational Study of GIOGer (Italian Group) Tj ETQq0 0 0 rBT /Overlock 10 Tf 5		
43	An RB-1 loss of function gene signature as a tool to predict response to neoadjuvant chemotherapy plus anti-HER2 agents: a substudy of the NeoALTO trial (BIG 1-06). <i>Therapeutic Advances in Medical Oncology</i> , 2019, 11, 175883591989160.	1.4	3
44	Nutritional management of older adults with gastrointestinal cancers: An International Society of Geriatric Oncology (SIOG) review paper. <i>Journal of Geriatric Oncology</i> , 2018, 9, 382-392.	0.5	43
45	Metabolomics in breast cancer: A decade in review. <i>Cancer Treatment Reviews</i> , 2018, 67, 88-96.	3.4	87
46	A gene expression signature of Retinoblastoma loss-of-function predicts resistance to neoadjuvant chemotherapy in ER-positive/HER2-positive breast cancer patients. <i>Breast Cancer Research and Treatment</i> , 2018, 170, 329-341.	1.1	17
47	Managing advanced HR-positive, HER2-negative breast cancer with CDK4/6 inhibitors in post-menopausal patients: is there a best sequence?. <i>Therapeutic Advances in Medical Oncology</i> , 2018, 10, 175883591881559.	1.4	5
48	An Italian Delphi study to evaluate consensus on adjuvant endocrine therapy in premenopausal patients with breast cancer: the ERA project. <i>BMC Cancer</i> , 2018, 18, 932.	1.1	6
49	Platinum-based Agent and Fluorouracil in Metastatic Breast Cancer: A Retrospective Monocentric Study with a Review of the Literature. <i>Anticancer Research</i> , 2018, 38, 4839-4845.	0.5	5
50	The role of abemaciclib in treatment of advanced breast cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2018, 10, 175883591877692.	1.4	14
51	Adjuvant endocrine therapy in premenopausal patients with hormone receptor-positive early breast cancer: Evidence evaluation and GRADE recommendations by the Italian Association of Medical Oncology (AIOM). <i>European Journal of Cancer</i> , 2018, 99, 9-19.	1.3	10
52	Serum Metabolomic Profiles Identify ER-Positive Early Breast Cancer Patients at Increased Risk of Disease Recurrence in a Multicenter Population. <i>Clinical Cancer Research</i> , 2017, 23, 1422-1431.	3.2	65
53	Cardiac safety, efficacy, and correlation of serial serum HER2-extracellular domain shed antigen measurement with the outcome of the combined trastuzumab plus CMF in women with HER2-positive metastatic breast cancer: results from the EORTC 10995 phase II study. <i>Breast Cancer Research and Treatment</i> , 2017, 163, 507-515.	1.1	3
54	Adherence to oral cancer therapy in older adults: The International Society of Geriatric Oncology (SIOG) taskforce recommendations. <i>Cancer Treatment Reviews</i> , 2017, 57, 58-66.	3.4	54

#	ARTICLE	IF	CITATIONS
55	Controversial issues in the management of older adults with early breast cancer. <i>Journal of Geriatric Oncology</i> , 2017, 8, 397-402.	0.5	9
56	Screening for Frailty in Older Patients With Early-Stage Solid Tumors: A Prospective Longitudinal Evaluation of Three Different Geriatric Tools. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2017, 72, 922-928.	1.7	26
57	Quality indicators in breast cancer care: An update from the EUSOMA working group. <i>European Journal of Cancer</i> , 2017, 86, 59-81.	1.3	163
58	De-escalating and escalating treatment beyond endocrine therapy in patients with luminal breast cancer. <i>Breast</i> , 2017, 34, S13-S18.	0.9	6
59	Is There Still a Role for First-Line Single Agent Endocrine Therapy in HR+ and HER2- Advanced Breast Cancer. <i>Breast Care</i> , 2017, 12, 288-289.	0.8	1
60	Demographic, tumor and clinical features of clinical trials versus clinical practice patients with HER2-positive early breast cancer: results of a prospective study. <i>Journal of Cancer Research and Clinical Oncology</i> , 2016, 142, 669-678.	1.2	14
61	Phase 1B/2 study of the HSP90 inhibitor AUY922 plus trastuzumab in metastatic HER2-positive breast cancer patients who have progressed on trastuzumab-based regimen. <i>Oncotarget</i> , 2016, 7, 37680-37692.	0.8	37
62	Challenges in the management of advanced, ER-positive, HER2-negative breast cancer. <i>Nature Reviews Clinical Oncology</i> , 2015, 12, 541-552.	12.5	121
63	Estimating the risk of chemotherapy toxicity in older patients with cancer: The role of the Vulnerable Elders Survey-13 (VES-13). <i>Journal of Geriatric Oncology</i> , 2015, 6, 272-279.	0.5	66
64	Continued value of adjuvant anthracyclines as treatment for early breast cancer. <i>Lancet Oncology</i> , The, 2015, 16, e362-e369.	5.1	50
65	Defining optimal duration and predicting benefit from chemotherapy in patients with luminal-like subtypes. <i>Breast</i> , 2015, 24, S136-S142.	0.9	17
66	Adjuvant Systemic Therapy in Older Breast Cancer Women: Can We Optimize the Level of Care?. <i>Cancers</i> , 2015, 7, 1191-1214.	1.7	13
67	A prognostic factor index for overall survival in patients receiving first-line chemotherapy for HER2-negative advanced breast cancer: An analysis of the ATHENA trial. <i>Breast</i> , 2014, 23, 656-662.	0.9	42
68	The best treatment for older patients with breast cancer. <i>European Journal of Cancer, Supplement</i> , 2013, 11, 299-300.	2.2	4
69	The continued evidence from overviews: What is the clinical utility?. <i>Breast</i> , 2013, 22, S8-S11.	0.9	1
70	Breast cancer in the elderly: which lessons have we learned?. <i>Future Oncology</i> , 2013, 9, 1871-1881.	1.1	18
71	Adjuvant Chemotherapy: Which Patient? What Regimen?. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2013, 33, 3-8.	1.8	2
72	Management of elderly patients with breast cancer: updated recommendations of the International Society of Geriatric Oncology (SIOG) and European Society of Breast Cancer Specialists (EUSOMA). <i>Lancet Oncology, The</i> , 2012, 13, e148-e160.	5.1	505

#	ARTICLE	IF	CITATIONS
73	First-Line Bevacizumab-Containing Therapy for Triple-Negative Breast Cancer: Analysis of 585 Patients Treated in the ATHENA Study. <i>Oncology</i> , 2012, 82, 218-227.	0.9	47
74	Exploration of serum metabolomic profiles and outcomes in women with metastatic breast cancer: A pilot study. <i>Molecular Oncology</i> , 2012, 6, 437-444.	2.1	73
75	Final results of a multicenter phase II clinical trial evaluating the activity of single-agent lapatinib in patients with HER2-negative metastatic breast cancer and HER2-positive circulating tumor cells. A proof-of-concept study. <i>Breast Cancer Research and Treatment</i> , 2012, 134, 283-289.	1.1	101
76	Inter- and intra-tumoral heterogeneity in DNA damage evaluated by comet assay in early breast cancer patients. <i>Breast</i> , 2012, 21, 336-342.	0.9	12
77	Uncovering the metabolomic fingerprint of breast cancer. <i>International Journal of Biochemistry and Cell Biology</i> , 2011, 43, 1010-1020.	1.2	77
78	Adjuvant systemic treatment for individual patients with triple negative breast cancer. <i>Breast</i> , 2011, 20, S135-S141.	0.9	14
79	Final overall survival results and effect of prolonged (1 year) first-line bevacizumab-containing therapy for metastatic breast cancer in the ATHENA trial. <i>Breast Cancer Research and Treatment</i> , 2011, 130, 133-143.	1.1	52
80	Bevacizumab and osteonecrosis of the jaw: incidence and association with bisphosphonate therapy in three large prospective trials in advanced breast cancer. <i>Breast Cancer Research and Treatment</i> , 2010, 122, 181-188.	1.1	232
81	Doxorubicin and Paclitaxel versus Fluorouracil, Doxorubicin and Cyclophosphamide as First-Line Therapy for Women with Advanced Breast Cancer: Long-Term Analysis of the Previously Published Trial. <i>Onkologie</i> , 2009, 32, 1-1.	1.1	13
82	ASCO 2009: What's New in Breast Cancer Therapy?. <i>Breast Care</i> , 2009, 4, 268-271.	0.8	0
83	Adjuvant chemotherapy – the dark side of clinical trials Have we learnt more?. <i>Breast</i> , 2009, 18, S18-S24.	0.9	6
84	Correlation of HER2 status between primary tumors and corresponding circulating tumor cells in advanced breast cancer patients. <i>Breast Cancer Research and Treatment</i> , 2009, 118, 523-530.	1.1	199
85	Taxanes in the elderly: Can we gain as much and be less toxic?. <i>Critical Reviews in Oncology/Hematology</i> , 2009, 70, 262-271.	2.0	18
86	Recent advances in systemic therapy. New diagnostics and biological predictors of outcome in early breast cancer. <i>Breast Cancer Research</i> , 2009, 11, 205.	2.2	66
87	Prognostic and Predictive Factors. <i>Cancer Treatment and Research</i> , 2009, 151, 13-30.	0.2	4
88	Topoisomerase II alpha as a marker predicting anthracyclines' activity in early breast cancer patients: Ready for the primetime?. <i>European Journal of Cancer</i> , 2008, 44, 2791-2798.	1.3	35
89	Taxanes Alone or in Combination With Anthracyclines As First-Line Therapy of Patients With Metastatic Breast Cancer. <i>Journal of Clinical Oncology</i> , 2008, 26, 1980-1986.	0.8	189
90	Evaluation of Tumor Response, Disease Control, Progression-Free Survival, and Time to Progression As Potential Surrogate End Points in Metastatic Breast Cancer. <i>Journal of Clinical Oncology</i> , 2008, 26, 1987-1992.	0.8	314

#	ARTICLE	IF	CITATIONS
91	Adjuvant Therapy in the Elderly: Making the Right Decision. <i>Journal of Clinical Oncology</i> , 2007, 25, 1870-1875.	0.8	75
92	Clinical decision making in breast cancer: TAM and aromatase inhibitors for older patients - a jungle?. <i>European Journal of Cancer</i> , 2007, 43, 2270-2278.	1.3	26
93	Management of breast cancer in elderly individuals: recommendations of the International Society of Geriatric Oncology. <i>Lancet Oncology</i> , The, 2007, 8, 1101-1115.	5.1	313
94	Metabolomics: Available Results, Current Research Projects in Breast Cancer, and Future Applications. <i>Journal of Clinical Oncology</i> , 2007, 25, 2840-2846.	0.8	217
95	A joined analysis of two European Organization for the Research and Treatment of Cancer (EORTC) studies to evaluate the role of pegylated liposomal doxorubicin (Caelyx®, C) in the treatment of elderly patients with metastatic breast cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2007, 61, 84-89.	2.0	34
96	Selection of chemotherapeutic drugs in adjuvant programs based on molecular profiles: Where do we stand?. <i>Critical Reviews in Oncology/Hematology</i> , 2007, 62, 1-8.	2.0	2
97	Using specific cytotoxics with a targeted mind. <i>Breast</i> , 2007, 16, 120-126.	0.9	35
98	Elderly Breast Cancer Patients: Adjuvant Chemotherapy and Adjuvant Endocrine Therapy. <i>Gynakologisch-geburtshilfliche Rundschau</i> , 2005, 45, 137-142.	0.9	2
99	Randomized, Controlled Trial Investigating Short-Term Health-Related Quality of Life With Doxorubicin and Paclitaxel Versus Doxorubicin and Cyclophosphamide As First-Line Chemotherapy in Patients With Metastatic Breast Cancer: European Organization for Research and Treatment of Cancer Breast Cancer Group, Investigational Drug Branch for Breast Cancer and the New Drug Development Group Study. <i>Journal of Clinical Oncology</i> , 2004, 22, 2576-2586.	0.8	52
100	Neulasta (pegfilgrastim): a once-per-cycle option for the management of chemotherapy-induced neutropenia. <i>Seminars in Oncology</i> , 2004, 31, 27-34.	0.8	36
101	Adjuvant Therapy in Elderly Patients with Breast Cancer. <i>Clinical Breast Cancer</i> , 2004, 5, 188-195.	1.1	15
102	What is the effect of systemic anticancer treatment on cognitive function?. <i>Lancet Oncology</i> , The, 2004, 5, 273-282.	5.1	91
103	Chemotherapy for metastatic breast cancer. <i>Current Opinion in Obstetrics and Gynecology</i> , 2004, 16, 37-41.	0.9	19
104	Doxorubicin-paclitaxel. <i>Cancer</i> , 2003, 97, 40-45.	2.0	42
105	Predictive molecular markers in the adjuvant therapy of breast cancer: state of the art in the year 2002. <i>International Journal of Clinical Oncology</i> , 2002, 7, 245-253.	1.0	11
106	Promising Results with Exemestane in the First-Line Treatment of Metastatic Breast Cancer: A Randomized Phase II EORTC Trial with a Tamoxifen Control. <i>Clinical Breast Cancer</i> , 2000, 1, S19-S21.	1.1	26
107	Oral doxifluridine plus levoleucovorin in elderly patients with advanced breast cancer. <i>Cancer</i> , 1998, 83, 1136-1141.	2.0	14
108	Breast Cancer Therapies in Development. <i>Drugs</i> , 1997, 54, 385-413.	4.9	13

#	ARTICLE	IF	CITATIONS
109	Glutamine supplementation in cancer patients receiving chemotherapy: A double-blind randomized study. <i>Nutrition</i> , 1997, 13, 748-751.	1.1	68
110	Adjuvant systemic therapy for breast cancer. <i>Current Opinion in Oncology</i> , 1996, 8, 478-484.	1.1	1
111	A dose-finding study of lanreotide (A somatostatin analog) in patients with colorectal carcinoma. , 1996, 78, 35-42.		6
112	Hormone therapy in advanced breast carcinoma: present and future trends. <i>Cancer Treatment Reviews</i> , 1994, 20, 241-258.	3.4	5